Back to discover
Drug

Sevoflurane

In clinical development
ClassGABA-A receptor; anion channel positive allosteric modulatorEmerging researchLate-stage development
Also known as Petrem, SevoFlo, Sevospire, Sojourn+7 more

Petrem, SevoFlo, Sevospire, Sojourn, Ultane, Sevofluran, Sevoflurano, Sévoflurane, 1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane, Fluoromethyl 2,2,2-trifluoro-1-(trifluromethyl)ethyl ether, Sevofluranum.

1
Research papers
18
Active clinical trials
23
Protein targets
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Response Surface Model Between Remimazolam and Sevoflurane; Comparison of the Minto and the Greco Model

Clinical trial2026-06-02Results expected Q2 2027 · ClinicalTrials.gov

Effect of Sevoflurane on Sweat Threshold in Children of Different Ages

Clinical trial2026-05-01Primary completion · ClinicalTrials.gov

Dynamic Effects of Different Anesthetic Agents on the Immune Function of Healthy Volunteers

Clinical trial2026-02-04Results expected Q3 2026 · ClinicalTrials.gov

Sevoflurane's Effect on Neurocognition Study

Clinical trial2026-01-30Completed · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Sevoflurane
Aliases & brands
PetremSevoFloSevospireSojournUltaneSevofluranSevofluranoSévoflurane1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propaneFluoromethyl 2,2,2-trifluoro-1-(trifluromethyl)ethyl etherSevofluranum
RxNorm CUI
36453
ChEMBL ID
CHEMBL1200694
ATC codes
N01AB08
UNII
38LVP0K73A
Primary mechanism
GABA-A receptor; anion channel positive allosteric modulator

Pharmacology & targets

23 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE MODULATORGlycine receptor (alpha-1/beta) positive modulator
POSITIVE MODULATORGlycine receptor (alpha-1/beta) positive modulator
OPENERPotassium channel subfamily K member 10 opener
OPENERPotassium channel subfamily K member 18 opener
OPENERPotassium channel subfamily K member 3 opener
OPENERPotassium channel subfamily K member 9 opener
OPENERPotassium channel subfamily K member 2 opener

Clinical trials

198 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
198
registered trials across all phases
LATEST COMPLETION 2026
18
Active studies
14
Recruiting
176
Late-stage (III+)
119
Completed
61
Discontinued
PHASE DISTRIBUTIONn = 198
Early Phase 13Phase 17Phase 1 / 23Phase 29Phase 2 / 33Phase 319Phase 470Phase N / A84

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Major research themes5
Acyltransferases1Myelin Sheath1Oligodendroglia1Receptors, Transferrin1Sevoflurane1
Journals, researchers & institutions
Top journals
  • Journal of advanced research1
Leading researchers
  • Cao Q1
  • Chen Y1
  • Dong H1
  • Jia S1
  • Liu H1
  • Liu Y1
  • Ou Z1
  • Su B1
Leading institutions
free-text, unnormalised
  • Binzhou Medical University Hospital1
  • Histology and Embryology & K.K. Leung Brain Research Centre1
  • State Key Laboratory of Cellular Stress Biology1
  • Xijing Hospital1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials